Cargando…

AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses

BACKGROUND: Adipocyte enhancer binding protein 1 (AEBP1) has been shown to be closely related to cancer progression; however research on its potential role in glioblastoma (GBM) remains limited. METHODS: Following an expression analysis of AEBP1 in GBM through the Oncomine database, other critical f...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Mingjian, Yu, Yuyu, Zhang, Ziqian, Chen, Zhenghong, Chen, Bin, Cheng, Yijun, Wei, Yongxu, Li, Jia, Shang, Hanbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667146/
https://www.ncbi.nlm.nih.gov/pubmed/34988166
http://dx.doi.org/10.21037/atm-21-5183
_version_ 1784614341276860416
author Liu, Mingjian
Yu, Yuyu
Zhang, Ziqian
Chen, Zhenghong
Chen, Bin
Cheng, Yijun
Wei, Yongxu
Li, Jia
Shang, Hanbing
author_facet Liu, Mingjian
Yu, Yuyu
Zhang, Ziqian
Chen, Zhenghong
Chen, Bin
Cheng, Yijun
Wei, Yongxu
Li, Jia
Shang, Hanbing
author_sort Liu, Mingjian
collection PubMed
description BACKGROUND: Adipocyte enhancer binding protein 1 (AEBP1) has been shown to be closely related to cancer progression; however research on its potential role in glioblastoma (GBM) remains limited. METHODS: Following an expression analysis of AEBP1 in GBM through the Oncomine database, other critical findings were accessed via The Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) databases. Specifically, in addition to identifying differentially expressed genes, the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) were further investigated. Additionally, a gene set enrichment analysis (GSEA) was performed to examine the enrichment pathways in the AEBP1 high-expression group. To examine the prognostic role of AEBP1 in GBM, survival information was obtained from the Chinese Glioma Genome Atlas (CGGA) database. Finally, the relationship between the expression of AEBP1 and immune infiltration in GBM was examined by using the “Gene Module”, “Survival Module”, and “SCNA Module” on the website “Tumor Immune Estimation Resource (TIMER)”. RESULTS: The Oncomine database revealed that AEBP1 was highly expressed in GBM. The prognostic analyses of 4 independent databases (i.e., TCGA, GTEx, Oncomine, and CGGA) revealed that AEBP1 was an independent predictable marker of GBM. The results of the GSEA showed that protein export, prion disease, cytokine receptor interaction, hematopoietic cell lineage, cell adhesion molecules, apoptosis, and the complement and coagulation cascades were differentially enriched in highly expressed AEBP1 phenotypes. Hence the conclusion is that the high expression of AEBP1 is closely correlated to poor prognosis of GBM. The immune analysis demonstrated that AEBP1 copy number alteration might affect immune infiltration in GBM tissues, and thus the survival outcomes of GBM patients. CONCLUSIONS: High AEBP1 expression in GBM is closely correlated to patient prognosis. AEBP1 is a potential therapeutic target for the inhibition of cancerous progression and the development of new immunotherapies for GBM.
format Online
Article
Text
id pubmed-8667146
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-86671462022-01-04 AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses Liu, Mingjian Yu, Yuyu Zhang, Ziqian Chen, Zhenghong Chen, Bin Cheng, Yijun Wei, Yongxu Li, Jia Shang, Hanbing Ann Transl Med Original Article BACKGROUND: Adipocyte enhancer binding protein 1 (AEBP1) has been shown to be closely related to cancer progression; however research on its potential role in glioblastoma (GBM) remains limited. METHODS: Following an expression analysis of AEBP1 in GBM through the Oncomine database, other critical findings were accessed via The Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) databases. Specifically, in addition to identifying differentially expressed genes, the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) were further investigated. Additionally, a gene set enrichment analysis (GSEA) was performed to examine the enrichment pathways in the AEBP1 high-expression group. To examine the prognostic role of AEBP1 in GBM, survival information was obtained from the Chinese Glioma Genome Atlas (CGGA) database. Finally, the relationship between the expression of AEBP1 and immune infiltration in GBM was examined by using the “Gene Module”, “Survival Module”, and “SCNA Module” on the website “Tumor Immune Estimation Resource (TIMER)”. RESULTS: The Oncomine database revealed that AEBP1 was highly expressed in GBM. The prognostic analyses of 4 independent databases (i.e., TCGA, GTEx, Oncomine, and CGGA) revealed that AEBP1 was an independent predictable marker of GBM. The results of the GSEA showed that protein export, prion disease, cytokine receptor interaction, hematopoietic cell lineage, cell adhesion molecules, apoptosis, and the complement and coagulation cascades were differentially enriched in highly expressed AEBP1 phenotypes. Hence the conclusion is that the high expression of AEBP1 is closely correlated to poor prognosis of GBM. The immune analysis demonstrated that AEBP1 copy number alteration might affect immune infiltration in GBM tissues, and thus the survival outcomes of GBM patients. CONCLUSIONS: High AEBP1 expression in GBM is closely correlated to patient prognosis. AEBP1 is a potential therapeutic target for the inhibition of cancerous progression and the development of new immunotherapies for GBM. AME Publishing Company 2021-11 /pmc/articles/PMC8667146/ /pubmed/34988166 http://dx.doi.org/10.21037/atm-21-5183 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Liu, Mingjian
Yu, Yuyu
Zhang, Ziqian
Chen, Zhenghong
Chen, Bin
Cheng, Yijun
Wei, Yongxu
Li, Jia
Shang, Hanbing
AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses
title AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses
title_full AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses
title_fullStr AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses
title_full_unstemmed AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses
title_short AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses
title_sort aebp1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667146/
https://www.ncbi.nlm.nih.gov/pubmed/34988166
http://dx.doi.org/10.21037/atm-21-5183
work_keys_str_mv AT liumingjian aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses
AT yuyuyu aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses
AT zhangziqian aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses
AT chenzhenghong aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses
AT chenbin aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses
AT chengyijun aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses
AT weiyongxu aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses
AT lijia aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses
AT shanghanbing aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses